Rahul Bhargava: Late-Breaking ASH 2025 Highlight
Rahul Bhargava, Director and Head of Hematology, Hematoncology and Stem Cell Transplant at Fortis Health Care , shared a post from ASH on LinkedIn:
“Late-Breaking ASH 2025 Highlight
MajesTEC-3: Teclistamab + Daratumumab (Tec-Dara) changing the game in Relapsed/Refractory Multiple Myeloma
One curve says it all — HR 0.17, 83.3% 3-year OS, median not reached!
We are witnessing the dawn of a new era where bispecifics and immune-based combinations are pushing survival boundaries beyond imagination.
The Tec-Dara regimen not only doubles durability compared to DPd/DVd but also offers hope for long-term disease control — a vision once unimaginable in RRMM.
The best part? These cutting-edge therapies are now available at the Fortis Advanced Center for Myeloma and Lymphoma Research — bringing the world’s most advanced science straight to our patients.
Truly unbelievable progress — the future of myeloma treatment is being rewritten.”
More posts on Hemostasis Today.
-
Dec 10, 2025, 14:57Elvira Grandone Announces the 1st ThrombUS+ Data Challenge
-
Dec 10, 2025, 14:18Love Preet Kalra on A Paradigm Shift in ICH
-
Dec 10, 2025, 13:37Aakanksha A: A Highlight of the Week Was Presenting Our ASH Poster
-
Dec 9, 2025, 23:37Thomas Reiser: Renew Your ISTH Membership for 2025
-
Dec 9, 2025, 13:34Aimn Abdujawad and Collaegues: A Quality Improvement Project to Optimize IVC Filter Use and Retrieval and Other More Projects at the ASH
-
Dec 9, 2025, 13:32Priya Prasad: A Night in the ER – When a Snakebite Teaches You the Power of Viscoelastic Testing
-
Dec 9, 2025, 13:30Maxime Dely: How Plasma Exchange Treats Severe Diseases – “A Simple Act Behind a Complex Therapy”
-
Dec 9, 2025, 13:27Riten Kumar: Highlights From Day 2 of ASH25
-
Dec 9, 2025, 13:25Dr. Abdul Muqtadir Abbasi: The Effect of Recombinant Factor VIIa Treatment in Non-Traumatic Intracranial Hemorrhage